Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O W Akkerman

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Hope rises out of despair: bedaquiline and linezolid for the treatment of drug-resistant TBJ Furin, O W Akkerman
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
The importance of knowing why TB patients stop anti-TB treatmentO W Akkerman, S Tiberi
The Journal of Antimicrobial Chemotherapy|December 4, 2018
Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosisO W Akkerman, J W C Alffenaar
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 29, 2021
Shortening MDR-TB treatment: is treating more patients with fewer drugs better?O W Akkerman, S Tiberi, J-W Alffenaar
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2024
Pancreatitis delays the absorption of first-line anti-TB drugsS Lever, O W Akkerman, B G J Dekkers
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2024
Post-TB lung disease: keep going beyond TB!E Pontali, O W Akkerman, D Zenner, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus ComorbidityB G J Dekkers, O W Akkerman, J W C Alffenaar
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 1, 2023
Characteristics and mortality of central nervous system TB in the Netherlands: a 15-year comparison with other forms of TBO W Akkerman, S van Het Hof, G de Vries, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|January 24, 2015
The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ familyM Hoppentocht, O W Akkerman, P Hagedoorn, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2024
Reply to 'Therapeutic drug monitoring for isoniazid and rifampicin exposure'O W Akkerman, H A M Kerstjens, M Kingma, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
Hope rises out of despair: bedaquiline and linezolid for the treatment of drug-resistant TBJ Furin, O W Akkerman
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 31, 2020
The importance of knowing why TB patients stop anti-TB treatmentO W Akkerman, S Tiberi
The Journal of Antimicrobial Chemotherapy|December 4, 2018
Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosisO W Akkerman, J W C Alffenaar
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 29, 2021
Shortening MDR-TB treatment: is treating more patients with fewer drugs better?O W Akkerman, S Tiberi, J-W Alffenaar
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2024
Pancreatitis delays the absorption of first-line anti-TB drugsS Lever, O W Akkerman, B G J Dekkers
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2024
Post-TB lung disease: keep going beyond TB!E Pontali, O W Akkerman, D Zenner, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus ComorbidityB G J Dekkers, O W Akkerman, J W C Alffenaar
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 1, 2023
Characteristics and mortality of central nervous system TB in the Netherlands: a 15-year comparison with other forms of TBO W Akkerman, S van Het Hof, G de Vries, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|January 24, 2015
The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ familyM Hoppentocht, O W Akkerman, P Hagedoorn, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2024
Reply to 'Therapeutic drug monitoring for isoniazid and rifampicin exposure'O W Akkerman, H A M Kerstjens, M Kingma, et al.
Pageof 4